TPST — Tempest Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$1.09
+$0.04 (+3.90%)
Tempest Therapeutics Inc (TPST) is a biotechnology company listed on NASDAQ. It is led by Stephen R. Brady J.D., LLM, based in 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005, with about 24 employees. Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Net income was -$3.5M. TPST currently screens at market cap $26.3M.
Use this TPST page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TPST quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TPST SEC filings page. Lician reads the product cache first so this HTML stays unique to Tempest Therapeutics Inc even when a live quote feed is slow.
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
TPST Key Statistics
Market Cap
$26.26M
Volume
68,975
Previous Close
$1.08
Day Range
$1.07 – $1.10
EPS
-$1.50
Revenue
$0.00
Net Income
-$41.84M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
24
TPST Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$41.84M | -$29.49M | -$35.71M | -$28.30M |
| EPS (Diluted) | -$1.50 | -$1.91 | -$3.09 | -$7.47 |
Total Assets
$41.49M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$30.27M
Operating Cash Flow
-$33.03M
Free Cash Flow
$0.00
Tempest Therapeutics Inc Company Information
- CEO, President & Director
- Stephen R. Brady J.D., LLM
- Headquarters
- 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
- Website
- www.tempesttx.com
- Phone
- 415 798 8589
- IPO / Founded
- 2012-11-12
- Sector
- Healthcare
- Industry
- Biotechnology